BSE filing, NSE: PARMAX. Summary written from the filing by ALFA Finder's alert engine.
Parmax Pharma Ltd: key numbers
- Share price
- ₹135.05
- Market cap
- ₹50.53 Cr
- Revenue (annual)
- ₹12.11 Cr
- Net profit (annual)
- ₹-4.16 Cr
- P/E (TTM)
- -42.3×Sector 46.1×
- Promoter holding
- 64.66%+33.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Parmax Pharma Ltd
All →Parmax Pharma Management Change
Parmax Pharma's independent director Ami Shah resigned effective October 28, 2026. The exit follows a change in management and control of the company.
Parmax Pharma Management Change
Parmax Pharma Ltd announced the resignation of Mr. Nikhil Uchat as an Independent Director of the Company, effective October 08, 2026.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd conducted its 32nd Annual General Meeting on September 29, 2026, covering routine business including financial statement adoption and board appointments.
Parmax Pharma Adverse Business Impact
Parmax Pharma reported a major fire incident at its Rajkot plant on September 28, 2026. Two employees were injured, and the company is currently assessing the financial damage.
Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Other other announcement announcements
All →Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.
Man Infraconstruction Other Announcement
Man Infraconstruction filed a Reg 32 quarterly statement confirming no deviation in use of preferential-warrant proceeds. No deviation or variation arose for the quarter ended September 30, 2026.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
Raama Finance Other Announcement
Raama Finance appointed M/s. Kumar Gaurav & Co. as statutory auditor for three months effective October 29, 2026. The routine appointment carries no financial impact.
Teja Engineering Industries Other Announcement
Teja Engineering Industries filed a non-applicability certificate for Reg 27(2) Corporate Governance for Q1 FY27. As an NSE Emerge-listed SME, the company is exempt from this periodic disclosure.
Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.